Show simple item record

dc.contributor.authorJones, RH
dc.contributor.authorCarucci, M
dc.contributor.authorCasbard, AC
dc.contributor.authorButler, R
dc.contributor.authorAlchami, F
dc.contributor.authorBale, CJ
dc.contributor.authorBezecny, P
dc.contributor.authorJoffe, J
dc.contributor.authorMoon, S
dc.contributor.authorTwelves, C
dc.contributor.authorVenkitaraman, R
dc.contributor.authorWaters, S
dc.contributor.authorHowell, Sacha J
dc.date.accessioned2019-11-19T16:01:05Z
dc.date.available2019-11-19T16:01:05Z
dc.date.issued2019en
dc.identifier.citationJones RH, Carucci M, Casbard AC, Butler R, Alchami F, Bale CJ, et al. Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trial. J Clin Oncol. 2019;37(15_suppl):1005-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.1005en
dc.identifier.urihttp://hdl.handle.net/10541/622450
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.1005en
dc.titleCapivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentVelindre Cancer Centre and Cardiff University, Cardiffen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record